GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » EV-to-FCF
中文

Mesoblast (Mesoblast) EV-to-FCF

: -13.34 (As of Today)
View and export this data going back to 2010. Start your Free Trial

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Mesoblast's Enterprise Value is $627.55 Mil. Mesoblast's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-47.05 Mil. Therefore, Mesoblast's EV-to-FCF for today is -13.34.

The historical rank and industry rank for Mesoblast's EV-to-FCF or its related term are showing as below:

MESO' s EV-to-FCF Range Over the Past 10 Years
Min: -35.02   Med: -8.29   Max: -2.56
Current: -13.72

During the past 13 years, the highest EV-to-FCF of Mesoblast was -2.56. The lowest was -35.02. And the median was -8.29.

MESO's EV-to-FCF is ranked worse than
100% of 389 companies
in the Biotechnology industry
Industry Median: 4.27 vs MESO: -13.72

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-23), Mesoblast's stock price is $6.00. Mesoblast's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $53.248. Therefore, Mesoblast's PE Ratio for today is 0.11.


Mesoblast EV-to-FCF Historical Data

The historical data trend for Mesoblast's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.27 -24.16 -9.28 -4.93 -10.46

Mesoblast Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.12 -8.80 -10.46 -3.32 -5.36

Competitive Comparison

For the Biotechnology subindustry, Mesoblast's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mesoblast EV-to-FCF Distribution

For the Biotechnology industry and Healthcare sector, Mesoblast's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Mesoblast's EV-to-FCF falls into.



Mesoblast EV-to-FCF Calculation

Mesoblast's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=627.553/-47.053
=-13.34

Mesoblast's current Enterprise Value is $627.55 Mil.
Mesoblast's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mesoblast  (NAS:MESO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Mesoblast's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.00/53.248
=0.11

Mesoblast's share price for today is $6.00.
Mesoblast's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $53.248.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Mesoblast EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Mesoblast's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast (Mesoblast) Business Description

Traded in Other Exchanges
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.